Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Gene Therapy Launch Delayed Again
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.